Form 4: Neumora Therapeutics Director Halawa Receives Repriced Stock Options

Director Alaa Halawa receives repriced stock options from Neumora Therapeutics, pending stockholder approval, as disclosed in a Form 4 filing.

Summary

• Alaa Halawa, a director at Neumora Therapeutics, received repriced stock options on February 13, 2025.
• The repricing, subject to stockholder approval, involves two sets of options: one vesting monthly from September 14, 2023, and another vesting on the earlier of June 13, 2025, or the next Annual Meeting following June 13, 2024.
• The exercise price for the repriced options is $1.69 per share.
• The repricing is contingent on Halawa remaining in service through August 13, 2026.
• The original exercise prices for the options were $17 and $9.95.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard executive compensation adjustment. The repricing could be seen as positive for incentivizing the director, but it also suggests the original options were underwater, indicating past stock performance issues.

Positives

• The repricing of stock options could incentivize Alaa Halawa to remain with Neumora Therapeutics.
• The lower exercise price of $1.69 may make the options more attractive to Halawa.

Negatives

• The repricing is contingent on stockholder approval, introducing uncertainty.
• The repricing is contingent on Halawa remaining in service through August 13, 2026, which may not be ideal for Halawa.

Risks

• Stockholder disapproval of the repricing could void the new terms.
• Halawa's departure before August 13, 2026, would also void the repricing.

Future Outlook

The repricing is subject to stockholder approval and Halawa's continued service through August 13, 2026.

Industry Context

Option repricing is a tool companies use to re-incentivize employees and board members when the stock price has declined significantly since the original grant date. This ensures that the options retain value and continue to serve as a motivator.

Comparison to Industry Standards

• Option repricing is a common practice in the biotech industry, especially for companies that have experienced a decline in stock price.
• Many companies reprice options to retain key personnel and align their interests with shareholders.
• Comparable companies that have repriced options include [hypothetical company A] and [hypothetical company B], which faced similar circumstances of stock price decline.

Stakeholder Impact

• Shareholders: The repricing could be viewed positively if it incentivizes Halawa to improve company performance, but negatively if seen as a giveaway.
• Employees: The repricing of options for board members and employees could improve morale and align interests.

Next Steps

• Stockholder approval of the option repricing.
• Halawa's continued service with Neumora Therapeutics through August 13, 2026.

Key Dates